This work suggests that in subjects at risk for AD and tauopathy, metformin’s pro-aggregation effects may mitigate its beneficial actions on tau phosphorylation: caution is thus warranted for metformin application in chronic therapies in elderly diabetic patients. The gene discussed is MAPT; the disease is Alzheimer disease.